[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-latent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-latent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100500264","phase-4-the-prevalence-of-iron-deficiency-and-the-effectiveness-of-ferinject-in-patients-with-hfpef-id-hfpef-100500264",false,"NCT05793996","The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency","ID-HFpEF","Inclusion Criteria:\n\n* Signed informed consent to participate in the study;\n* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);\n* Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and\u002For functional disorders of the heart consistent with the presence of LV diastolic dysfunction\u002Fincreased LV filling pressure, including elevated levels of natriuretic peptide;\n* Screening ferritin below 100 µg\u002FL, or below 300 µg\u002FL when transferrin saturation (TSAT) is below 20%;\n* Screening haemoglobin (Hb) at the time of switching on ( 90-150 g\u002Fl).\n\nExclusion Criteria:\n\n* Uncontrolled arterial hypertension;\n* Аnemia not related to iron deficiency;\n* Аnemia with a hemoglobin level of less than 90 g\u002Fl;\n* Less than 1 year after acute myocardial infarction;\n* Less than 1 year after acute cerebral circulation disorder;\n* Less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology;\n* Chronic alcoholism (including alcoholic heart disease), mental disorders;\n* Severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency (glomerular filtration rate less than 15 ml\u002Fmin\u002F1.73 m2);\n* Known active infection, clinically significant bleeding, active malignancy;\n* Severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);\n* Severe bronchial asthma, COPD in the acute stage;\n* Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;\n* Blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.",[27,28],"Chronic Heart Failure","Iron Deficiency, Latent",[30,31,32,33],"HFpEF","iron deficiency","ferric carboxymaltose","Ferinject","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2023-04-28",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER"]